This invention relates generally to an apparatus for the treatment of sphincters, and more specifically to an apparatus that treats esophageal sphincters.
Gastroesophageal reflux disease (GERD) is a common gastroesophageal disorder in which the stomach contents are ejected into the lower esophagus due to a dysfunction of the lower esophageal sphincter (LES). These contents are highly acidic and potentially injurious to the esophagus resulting in a number of possible complications of varying medical severity. The reported incidence of GERD in the U.S. is as high as 10% of the population (Castell D O; Johnston B T: Gastroesophageal Reflux Disease: Current Strategies For Patient Management. Arch Fam Med, 5(4):221-7; (1996 April)).
Acute symptoms of GERD include heartburn, pulmonary disorders and chest pain. On a chronic basis, GERD subjects the esophagus to ulcer formation, or esophagitis and may result in more severe complications including esophageal obstruction, significant blood loss and perforation of the esophagus. Severe esophageal ulcerations occur in 20-30% of patients over age 65. Moreover, GERD causes adenocarcinoma, or cancer of the esophagus, which is increasing in incidence faster than any other cancer (Reynolds J C: Influence Of Pathophysiology, Severity, And Cost On The Medical Management Of Gastro esophageal Reflux Disease. Am J Health Syst Pharm, 53(22 Suppl 3):S5-12 (1996 Nov. 15)).
One of the possible causes of GERD may be aberrant electrical signals in the LES or cardia of the stomach. Such signals may cause a higher than normal frequency of relaxations of the LES allowing acidic stomach contents to be repeatedly ejected into the esophagus and cause the complications described above. Research has shown that unnatural electrical signals in the stomach and intestine can cause reflux events in those organs (Kelly K A, et al: Duodenal-gastric Reflux and Slowed Gastric Emptying by Electrical Pacing of the Canine Duodenal Pacesetter Potential. Gastroenterology. 1977 March; 72(3): 429-433). In particular, medical research has found that sites of aberrant electrical activity or electrical foci may be responsible for those signals (Karlstrom L H, et al.: Ectopic Jejunal Pacemakers and Enterogastric Reflux after Roux Gastrectomy: Effect Intestinal Pacing. Surgery. 1989 September; 106(3): 486-495). Similar aberrant electrical sites in the heart which cause contractions of the heart muscle to take on life threatening patterns or dysrhythmias can be identified and treated using mapping and ablation devices as described in U.S. Pat. No. 5,509,419. However, there is no current device or associated medical procedure available for the electrical mapping and treatment of aberrant electrical sites in the LBS and stomach as a means for treating GERD.
Current drug therapy for GERD includes histamine receptor blockers which reduce stomach acid secretion and other drugs which may completely block stomach acid. However, while pharmacologic agents may provide short term relief, they do not address the underlying cause of LES dysfunction.
Invasive procedures requiring percutaneous introduction of instrumentation into the abdomen exist for the surgical correction of GERD. One such procedure, Nissen fundoplication, involves constructing a new “valve” to support the LES by wrapping the gastric fundus around the lower esophagus. Although the operation has a high rate of success, it is an open abdominal procedure with the usual risks of abdominal surgery including: postoperative infection, herniation at the operative site, internal hemorrhage and perforation of the esophagus or of the cardia. In fact, a recent 10 year, 344 patient study reported the morbidity rate for this procedure to be 17% and mortality 1% (Urschel, J D: Complications Of Antireflux Surgery, Am J Surg 166(1): 68-70; (1993 July)). This rate of complication drives up both the medical cost and convalescence period for the procedure and may exclude portions of certain patient populations (e.g., the elderly and immuno-compromised).
Efforts to perform Nissen fundoplication by less invasive techniques have resulted in the development of laparoscopic Nissen fundoplication. Laparoscopic Nissen fundoplication, reported by Dallemagne et al. Surgical Laparoscopy and Endoscopy, Vol. 1, No. 3, (1991), pp. 138-43 and by Hindler et al. Surgical Laparoscopy and Endoscopy, Vol. 2, No. 3, (1992), pp. 265-272, involves essentially the same steps as Nissen fundoplication with the exception that surgical manipulation is performed through a plurality of surgical cannula introduced using trocars inserted at various positions in the abdomen.
Another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,088,979. In this procedure an invagination device containing a plurality of needles is inserted transorally into the esophagus with the needles in a retracted position. The needles are extended to engage the esophagus and fold the attached esophagus beyond the gastroesophageal junction. A remotely operated stapling device, introduced percutaneously through an operating channel in the stomach wall, is actuated to fasten the invaginated gastroesophageal junction to the surrounding involuted stomach wall.
Yet another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,676,674. In this procedure, invagination is done by a jaw-like device and fastening of the invaginated gastroesophageal junction to the fundus of the stomach is done via a transoral approach using a remotely operated fastening device, eliminating the need for an abdominal incision. However, this procedure is still traumatic to the LES and presents the postoperative risks of gastroesophageal leaks, infection and foreign body reaction, the latter two sequela resulting when foreign materials such as surgical staples are implanted in the body.
While the methods reported above are less invasive than an open Nissen fundoplication, some still involve making an incision into the abdomen and hence the increased morbidity and mortality risks and convalescence period associated with abdominal surgery. Others incur the increased risk of infection associated with placing foreign materials into the body. All involve trauma to the LES and the risk of leaks developing at the newly created gastroesophageal junction.
Besides the LES, there are other sphincters in the body which if not functionally properly can cause disease states or otherwise adversely affect the lifestyle of the patient. Reduced muscle tone or otherwise aberrant relaxation of sphincters can result in a laxity of tightness disease states including, but not limited to, urinary incontinence.
There is a need to provide an apparatus to treat a sphincter and reduce a frequency of sphincter relaxation. Another need exists for an apparatus to create controlled cell necrosis in a sphincter tissue underlying a sphincter mucosal layer. Yet another need exists for an apparatus to create cell necrosis in a sphincter and minimize injury to a mucosal layer of the sphincter. There is another need for an apparatus to controllably produce lesions in a sphincter without creating a permanent impairment of the sphincter's ability to achieve a physiologically normal state of closure. Still a further need exists for an apparatus to create a tightening of a sphincter without permanently damaging anatomical structures near the sphincter. There is still another need for an apparatus to create cell necrosis in a lower esophageal sphincter to reduce a frequency of reflux of stomach contents into an esophagus.
The invention provides an apparatus to treat tissue at or near a sphincter.
According to one aspect of the invention, the apparatus comprises an elongated member having at least one lumen including an inflation lumen, and a basket assembly including a first and a second arm. At least one of the first and second arms includes a fluid lumen having an aperture for conveying a fluid from the basket assembly. The basket assembly is coupled to the elongated member and has a deployed and a non-deployed configuration. According to this aspect of the invention, an inflatable member is coupled to the elongated member and positioned in an interior of the basket assembly. The inflatable member is coupled to the inflation lumen and has a deployed and a non-deployed state. In the deployed state, the inflatable member expands the basket assembly to the basket assembly deployed configuration into contact with tissue. Also according to this aspect of the invention, a source of fluid is coupled to the fluid lumen for conveyance of fluid through the aperture.
In various embodiments, the fluid can comprise, e.g., an electrolytic solution, and/or an anti-infection agent, and/or an echogenic media, and/or a steroid, and/or an anesthetic, and/or a medicament, and/or a tissue cooling agent.
In one embodiment, the source can comprise a drug delivery device.
In one embodiment, expansion of the basket assembly to the basket assembly deployed configuration dilates tissue at or near the sphincter.
These and other objects of the invention are provided in a sphincter treatment apparatus. The apparatus includes an elongated member with lumen and a basket assembly with first and second arms. The basket assembly is coupled to the elongated member and has deployed and non-deployed configurations. An inflatable member is coupled to the elongated member and positioned in an interior of state, the inflatable member expands the basket assembly to its deployed configuration. A first energy delivery device is positionable in the first arm and advanceable from the first arm to a selected treatment site. A second energy delivery device is positionable in the second arm and advanceable from the second arm to a selected treatment site the basket assembly. The inflatable member has deployed and non-deployed states and is coupled to the elongated member lumen. In the deployed state, the inflatable member expands the basket assembly to its deployed configuration. A first energy delivery device is positionable in the first arm and advanceable from the first arm to a selected treatment site. A second energy delivery device is positionable in the second arm and advanceable from the second arm to a selected treatment site.
Referring now to
As illustrated in
Shaft 18 has a proximal and distal end 18′ and 18″ and has sufficient length to position expandable basket assembly 20 in the LES and/or stomach including the cardia using a transoral approach. Typical lengths for shaft 18 include, but are not limited to, a range of 40-180 cms. In various embodiments, shaft 18 is flexible, articulated and steerable and can contain fiber optics (including illumination and imaging fibers), fluid and gas paths, and sensor and electronic cabling. In one embodiment, shaft 18 can be a multi-lumen catheter, as is well known to those skilled in the art. Shaft 18 cam also be coupled to a proximal handle 31, which in various embodiments can include handle ports 31′ for balloon inflation, and the delivery of cooling and other fluids described herein. Ports 31′ can include but are not limited to valves (one-way or two-way), luer fittings and other adaptors and medical fittings known in the art.
Basket assembly 20 is configured to be positionable in a sphincter 16 such as the LES or adjacent anatomical structure, such as the cardia of the stomach. Basket assembly 20 has a central longitudinal axis 20′ and is moveable between contracted and expanded positions (also called non-deployed and deployed configurations) substantially there along. In various embodiments, this can be accomplished without a balloon using a pullwire mechanism (not shown) which can include a ratchet mechanism for locking the pull wire in given position. At least portions of apparatus 10 may be sufficiently radiopaque in order to be visible under fluoroscopy and/or sufficiently echogenic to be visible under ultrasonography. Also as will be discussed herein, apparatus 10 can include visualization capability including, but not limited to, a viewing scope, an expanded eyepiece, fiber optics, video imaging and the like. Such viewing means may be delivered through a central lumen 19 within elongated shaft 18 or within or alongside basket assembly 20. In various embodiments, elongated shaft 18 may have multiple lumens 19 which can be configured for the advancement of various elongated medical devices 23 to a treatment site 12 or other area in the body. Elongated medical devices 23 can include guidewires, drug delivery catheters, manometry catheters, pH monitoring catheters, endoscopes, viewing scopes and the like. Lumens 19 can also be configured for the delivery of liquids (including cooling liquids), gases and drugs or medicaments 13 to a treatment site 12 or other area of the body. In one embodiment lumen 19 can be configured as an inflation lumen described herein to inflate inflatable member 25 using a liquid or gaseous inflation media.
Referring now to
In another embodiment, arms 21 may have an external layer of the texturized material that has sufficient friction to at least partially immobilize the area of sphincter wall near and around that contacted by an arm 21. Suitable materials for the texturized material include knitted Dacron® and Dacron velour.
In one embodiment, illustrated in
Turning now to a discussion of energy delivery, suitable energy sources 24 and energy delivery devices 22 that can be employed in one or more embodiments of the invention include: (i) a radiofrequency (RF) source coupled to an RF electrode, (ii) a coherent source of light coupled to an optical fiber, (iii) an incoherent light source coupled to an optical fiber, (iv) a heated fluid coupled to a catheter with a closed channel configured to receive the heated fluid, (v) a heated fluid coupled to a catheter with an open channel configured to receive the heated fluid, (vi) a cooled fluid coupled to a catheter with a closed channel configured to receive the cooled fluid, (vii) a cooled fluid coupled to a catheter with an open channel configured to receive the cooled fluid, (viii) a cryogenic fluid, (ix) a resistive heating source coupled to a heating element positioned either on the arms to heat tissue directly or within the balloon to heat the inflation medium, (x) a microwave source providing energy from 915 MHz to 2.45 GHz and coupled to a microwave antenna, or (xi) an ultrasound power source coupled to an ultrasound emitter, wherein the ultrasound power source produces energy in the range of 300 KHZ to 3 GHz. For ease of discussion for the remainder of this specification, the power source utilized is an RF source and energy delivery device 22 is one or more RF electrodes 22. However, all of the other herein mentioned energy sources and energy delivery devices are equally applicable to sphincter treatment apparatus 10.
For the case of RF energy, RF electrode 22 may be operated in either bipolar or monopolar mode with a ground pad electrode. In a monopolar mode of delivering RF energy, a single electrode 22 is used in combination with an indifferent electrode patch that is applied to the body to form the other electrical contact and complete an electrical circuit. Bipolar operation is possible when two or more electrodes 22 are used. Electrodes 22 can be attached to an electrode delivery member (describe herein) by the use of soldering methods which are well known to those skilled in the art. Suitable solders include Megabond Solder supplied by the Megatrode Corporation (Milwaukee, Wis.). Other joining methods include, but are not limited to, welding and adhesive bonding (including the use of conductive adhesives known in the art). In various embodiments, the electrode to delivery member joint can be conductive (for the case where electrodes 22 are activated simultaneously) or nonconductive (for the case where electrodes 22 are activated individually). In the latter case, electrodes are attached to individual conductors and are electrically isolated from each other (e.g. other electrodes).
Referring now to
RF electrodes 22 can have a variety of shapes and sizes. Possible shapes include, but are not limited to, circular, rectangular, conical and pyramidal. Electrode surfaces can be smooth or textured and concave or convex. The conductive surface area of electrode 22 can range from 0.1 cm2 to 100 cm2. It will be appreciated that other geometries and surface areas may be equally suitable.
Referring now to
Suitable materials for RF electrodes 22 include, but are not limited to, 304 stainless steel and other stainless steels known to those skilled in the art. Suitable materials for insulation sleeve 27 include, but are not limited to, polyimides and parylene; and in a preferred embodiment, PET (polyethylene terephthalate).
Referring back to
Referring now to
Referring now to
Referring now
Similarly, it may also be desirable to cool all or a portion of RF electrode 22. The rapid delivery of heat through RF electrodes 22 may result in the build up of charred biological matter on RF electrodes 22 (from contact with tissue and fluids e.g., blood) that impedes the flow of both thermal and electrical energy from RF electrodes 22 to adjacent tissue and causes an electrical impedance rise beyond a cutoff value set on RF energy source 24. A similar situation may result from the desiccation of tissue adjacent to RF electrodes 22. Cooling of RF electrodes 22 can be accomplished by the use of cooling media 35.
Additionally, electrodes 22 can be hollow and used to introduce electrolytic solutions into sphincter 16 and sphincter wall 17 through the use of ports 21′″ disposed on electrodes 22 that are fluidically coupled to cooling media 35 and/or cooling media reservoir 35′. Suitable electrolytic solutions include saline; and solutions of calcium salts, potassium salts, and the like. Electrolytic solutions enhance the electrical conductivity of the targeted tissue at the treatment site 12. When a highly conductive fluid such as an electrolytic solution is infused into tissue the electrical resistance of the infused tissue is reduced, in turn, increasing the electrical conductivity of the infused tissue. As a result, there is little tendency for tissue surrounding RF electrode 22 to desiccate (a condition described herein that increases the electrical resistance of tissue) resulting in a large increase in the capacity of the tissue to carry RF energy.
One or more sensors 29 may be positioned adjacent to or on RF electrode 22 for sensing the temperature of sphincter tissue at treatment site 12. More specifically, sensors 29 permit accurate determination of the surface temperature and/or interior temperature of sphincter 16. This information can be used to regulate both the delivery of energy and cooling media 35 to sphincter 16. In various embodiments, sensors 29 can be positioned at any position on balloon 25, basket assembly 20 or at an RF electrode 22. Suitable sensors that may be used include but are not limited to, thermocouples, fiber optics, resistive wires, thermocouple IR detectors, and the like. Suitable thermocouples include T type with copper constantene, J type, F type and K types as are well known those skilled in the art.
As illustrated in
Another geometric configuration of balloon 25 is illustrated in
Referring now to
In one embodiment, all RF electrodes 22 can be coupled to the same electrode advancement and retraction member 32. Alternatively, various numbers and groups of RF electrodes can be coupled to different electrode advancement and retraction members 32. In the embodiment illustrated in
Referring now to
Also when the energy source is RF, energy source 24, which will now be referred to as RF energy source 24, may have multiple channels, delivering separately modulated power to each RF electrode 22. This configuration reduces preferential heating that occurs when more energy is delivered to a zone of greater conductivity and less heating occurs around RF electrodes 22 which are placed into less conductive tissue. If the level of tissue hydration or the blood infusion rate in the tissue is uniform, a single channel RF energy source 24 may be used to provide power for generation of lesions 14 relatively uniform in size.
During introduction of apparatus 10, basket assembly 20 is in a contracted or non-deployed state. Once apparatus 10 is properly positioned at the treatment site 12, balloon 25 is inflated, basket assembly 20 is deployed (expanded) and HF electrodes 22 are then introduced into sphincter wall 17. The depth of needle penetration is selectable from a range of about 0.5 to 5 mms and can be accomplished by an indexed movable fitting coupled to shaft 18.
Referring now to
RF energy flowing through sphincter or other tissue causes heating of the tissue due to absorption of the RF energy by the tissue and ohmic heating due to electrical resistance of the tissue. This heating can cause injury to the affected cells which can be substantial enough to cause cell death, a phenomenon also known as cell necrosis. For ease of discussion for the remainder of this application, cell injury will include all cellular effects resulting from the delivery of energy from RF electrode 22 up to, and including, cell necrosis. Cell injury can be accomplished as a relatively simple medical procedure with local anesthesia. In one embodiment, cell injury proceeds to a depth of approximately 1-4 mms from the surface of the mucosal layer 17′ of sphincter 16 or that of an adjoining anatomical structure.
The diagnostic phase of the procedure can be performed using a variety of diagnostic methods, including, but not limited to, the following: (i) visualization of the interior surface of the esophagus via an endoscope or other viewing apparatus inserted into the esophagus, (ii) visualization of the interior morphology of the esophageal wall using ultrasonography to establish a baseline morphology for the tissue to be treated, (iii) impedance measurement to determine the electrical conductivity between the esophageal mucosal layers 17′ and apparatus 10, (iv) esophageal pressure measurement to determine location of the LES using esophageal manometry methods which may include the use of a manometry catheter and measurement system such as that sold by Medtronic Synectics (Stockholm, Sweden), (v) measurement and surface mapping of the electropotential of the LES during varying time periods which may include such physiological events as depolarization, contraction and repolarization of LES smooth muscle tissue. This latter technique is done to determine target treatment sites 12 in the LES or adjoining anatomical structures.
In the treatment phase of the procedure, the delivery of energy to treatment site 12 can be conducted under feedback control, manually or by a combination of both. Feedback control (described herein) enables apparatus 10 to be positioned and retained in the esophagus during treatment with minimal attention by the physician. RF electrodes 22 can be multiplexed in order to treat the entire targeted treatment site 12 or only a portion thereof. Feedback can be included and is achieved by the use of one or more of the following methods: (i) visualization, (ii) impedance measurement, (iii) ultrasonography, (iv) temperature measurement; and, (v) sphincter contractile force (e.g. pressure) measurement via manometry. The feedback mechanism permits the selected on-off switching of different RF electrodes 22 in a desired pattern, which can be sequential from one RF electrode 22 to an adjacent RF electrode 22, or can jump around between non-adjacent RF electrodes 22. Individual RF electrodes 22 can be multiplexed and volumetrically controlled by a controller.
The area and magnitude of cell injury in the LES or sphincter 16 can vary. However, it is desirable to deliver sufficient energy to the targeted treatment site 12 to be able to achieve tissue temperatures in the range of 55-95° C. and produce lesions 14 at depths ranging from 1-4 mms from the interior surface of the LES or sphincter wall 17. Typical energies delivered to the sphincter wall 17 include, but are not limited to, a range between 100 and 50,000 joules per RF electrode 22. It is also desirable to deliver sufficient energy such that the resulting lesions 14 have a sufficient magnitude and area of cell injury to cause an infiltration of lesion 14 by fibroblasts, myofibroblasts, macrophages and other cells involved in the tissue healing process. These cells cause a contraction of tissue around lesion 14, decreasing its volume and/or altering the biomechanical properties at lesion 14 so as to result in a tightening of LES or sphincter 16.
From a diagnostic standpoint, it is desirable to image the interior surface and wall 17 of the LES or other sphincter 16, including the size and position of created lesions 14. A map of these lesions 14 can inputted to a controller and used to direct the delivery of energy to the treatment site. This can be accomplished through the use of ultrasonography (a known procedure) which involves the use of an ultrasound energy source coupled to one or more ultrasound transducers that can be positioned on balloon 25 or basket assembly 20. An output is associated with the ultrasound energy source.
It is desirable that lesions 14 be predominantly located in the smooth muscle layer of selected sphincter 16 at the depths ranging from 1 to 4 mms from the interior surface of sphincter wall 17. However, lesions 14 can vary both in number and position within sphincter 16. It may be desirable to produce a pattern of multiple lesions 14 within the sphincter smooth muscle tissue in order to obtain a selected degree of tightening of the LES or other sphincter 16. Typical lesion patterns include, but are not limited to, (i) a concentric circle of lesions 14 formed at different levels in the smooth muscle layer evenly spaced along the radial axis of sphincter 16, (ii) a wavy or folded circle of lesions 14 at varying depths in the smooth muscle layer evenly spaced along the radial axis of sphincter 16, (iii) lesions 14 randomly distributed at varying depths in the smooth muscle, but evenly spaced in a radial direction; and, (iv) an eccentric pattern of lesions 14 in one or more radial locations in the smooth muscle wall. Accordingly, the depth of RF and thermal energy penetration sphincter 16 is controlled and selectable. The selective application of energy to sphincter 16 may be the even penetration of RF energy to the entire targeted treatment site 12, a portion of it, or applying different amounts of RF energy to different sites depending on the condition of sphincter 16. If desired, the area of cell injury can be substantially the same for every treatment event.
Referring now to
In one embodiment, apparatus 10 is coupled to an open or closed loop feedback system. Referring now to
The temperature of the sphincter wall tissue, or of RF electrode 122 is monitored, and the output power of energy source 124 adjusted accordingly. The physician can, if desired, override the closed or open loop system. A microprocessor 136 can be included and incorporated in the closed or open loop system to switch power on and off, as well as modulate the power. The closed loop system utilizes microprocessor 136 to serve as a controller 138, monitor the temperature, adjust the RF power, analyze the result, refeed the result, and then modulate the power.
With the use of sensor 129 and the feedback control system a tissue adjacent to RF electrode 122 can be maintained at a desired temperature for a selected period of time without causing a shut down of the power circuit to RF electrode 122 due to the development of excessive electrical impedance at RF electrode 122 or adjacent tissue as is discussed herein. Each RF electrode 122 is connected to resources which generate an independent output. The output maintains a selected energy at RF electrode 122 for a selected length of time.
Current delivered through RF electrode 122 is measured by current sensor 140. Voltage is measured by voltage sensor 142. Impedance and power are then calculated at power and impedance calculation device 144. These values can then be displayed at user a interface and display 146. Signals representative of power and impedance values are received by controller 138.
A control signal is generated by controller 138 that is proportional to the difference between an actual measured value (e.g. an analog or digital signal indicative of temperature, power, etc.) and a desired value. The control signal is used by power circuits 148 to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes 122.
In a similar manner, temperatures detected at sensor 129 provide feedback for maintaining a selected power. The temperature at sensor 129 is used as a safety means to interrupt the delivery of energy when maximum pre-set temperatures are exceeded. The actual temperatures are measured at temperature measurement device 150, and the temperatures are displayed at user interface and display 146. A control signal is generated by controller 138 that is proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used by power circuits 148 to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor 129. A multiplexer can be included to measure current, voltage and temperature, at the sensor 129, and energy can be delivered to RF electrode 122 in monopolar or bipolar fashion.
Controller 138 can be a digital or analog controller, or a computer with software. When controller 138 is a computer it can include a CPU coupled through a system bus. This system can include a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in the art. Also coupled to the bus is a program memory and a data memory.
User interface and display 146 includes operator controls and a display. Controller 138 can be coupled to imaging systems including, but not limited to, ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like. Further, direct visualization and tactile imaging can also be utilized.
The output of current sensor 140 and voltage sensor 142 are used by controller 138 to maintain a selected power level at RF electrode 122. The amount of RF energy delivered controls the amount of power. A profile of the power delivered to electrode 122 can be incorporated in controller 138 and a preset amount of energy to be delivered may also be profiled.
Circuitry, software and feedback to controller 138 result in process control, the maintenance of the selected power setting which is independent of changes in voltage or current, and is used to change the following process variables: (i) the selected power setting, (ii) the duty cycle (e.g., on-off time), (iii) bipolar or monopolar energy delivery; and, (iv) fluid delivery, including flow rate and pressure. These process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored at sensor 129.
Referring now to
Microprocessor 136 sequentially receives and stores digital representations of impedance and temperature. Each digital value received by microprocessor 136 corresponds to different temperatures and impedances.
Calculated power and impedance values can be indicated on user interface and display 146. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared by microprocessor 136 to power and impedance limits. When the values exceed predetermined power or impedance values, a warning can be given on user interface and display 146, and additionally, the delivery of RF energy can be reduced, modified or interrupted. A control signal from microprocessor 136 can modify the power level supplied by energy source 124.
The control of the delivery of a cooling solution to RF electrode 122 and/or tissue site 112 is done in the following manner. During the application of energy, temperature measurement device 150 measures the temperature of tissue site 112 and/or RF electrode 122. A comparator 166 receives a signal representative of the measured temperature and compares this value to a pre-set signal representative of the desired temperature. If the tissue temperature is too high, comparator 166 sends a signal to a flow regulator 160 (connected to an electronically controlled micropump, not shown) representing a need for an increased cooling solution flow rate. If the measured temperature has not exceeded the desired temperature, comparator 166 sends a signal to flow regulator 160 to maintain the cooling solution flow rate at its existing level.
The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be defined by the following claims and their equivalents.
This application is a continuation of U.S. application Ser. No. 14/015,993, filed Aug. 30, 2013 (now U.S. Pat. No. 8,894,646), which is a continuation of U.S. application Ser. No. 11/580,543, filed Oct. 13, 2006, now abandoned, which is a divisional of U.S. application Ser. No. 10/728,684, filed Dec. 5, 2003 (now U.S. Pat. No. 7,125,407), which is a divisional of U.S. application Ser. No. 09/776,140, filed Feb. 2, 2001 (now U.S. Pat. No. 6,673,070), which is a continuation of U.S. application Ser. No. 09/235,060, filed Jan. 20, 1999 (now U.S. Pat. No. 6,254,598), which is a continuation-in-part of U.S. application Ser. No. 09/026,316, filed Feb. 19, 1998 (now U.S. Pat. No. 6,056,744).
Number | Name | Date | Kind |
---|---|---|---|
1798902 | Raney | Mar 1931 | A |
3517128 | Hines | Jun 1970 | A |
3901241 | Allen, Jr. | Aug 1975 | A |
4011872 | Komiya | Mar 1977 | A |
4196724 | Wirt et al. | Apr 1980 | A |
4411266 | Cosman | Oct 1983 | A |
4423812 | Sato | Jan 1984 | A |
4532924 | Auth et al. | Aug 1985 | A |
4565200 | Cosman | Jan 1986 | A |
4705041 | Kim | Nov 1987 | A |
4790310 | Ginsburg et al. | Dec 1988 | A |
4901737 | Toone | Feb 1990 | A |
4906203 | Margrave et al. | Mar 1990 | A |
4907589 | Cosman | Mar 1990 | A |
4943290 | Rexroth et al. | Jul 1990 | A |
4947842 | Marchosky et al. | Aug 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4966597 | Cosman | Oct 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
5019075 | Spears et al. | May 1991 | A |
5035696 | Rydell | Jul 1991 | A |
5046512 | Murchie | Sep 1991 | A |
5047028 | Qian | Sep 1991 | A |
5057107 | Parins et al. | Oct 1991 | A |
5078717 | Parins et al. | Jan 1992 | A |
5083565 | Parins | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5088979 | Filipi et al. | Feb 1992 | A |
5094233 | Brennan | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5122137 | Lennox | Jun 1992 | A |
5125928 | Parins et al. | Jun 1992 | A |
5156151 | Imran | Oct 1992 | A |
5190541 | Abele et al. | Mar 1993 | A |
5197963 | Parins | Mar 1993 | A |
5197964 | Parins | Mar 1993 | A |
5205287 | Erbel et al. | Apr 1993 | A |
5215103 | Desai | Jun 1993 | A |
5232444 | Just et al. | Aug 1993 | A |
5236413 | Feiring | Aug 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5254126 | Filipi et al. | Oct 1993 | A |
5256138 | Vurek et al. | Oct 1993 | A |
5257451 | Edwards et al. | Nov 1993 | A |
5263493 | Avital | Nov 1993 | A |
5275162 | Edwards et al. | Jan 1994 | A |
5275608 | Forman et al. | Jan 1994 | A |
5275610 | Eberbach | Jan 1994 | A |
5277201 | Stern | Jan 1994 | A |
5281216 | Klicek | Jan 1994 | A |
5281217 | Edwards et al. | Jan 1994 | A |
5281218 | Imran | Jan 1994 | A |
5290286 | Parins | Mar 1994 | A |
5292321 | Lee | Mar 1994 | A |
5293869 | Edwards et al. | Mar 1994 | A |
5309910 | Edwards et al. | May 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5314466 | Stern et al. | May 1994 | A |
5316020 | Truffer | May 1994 | A |
5324284 | Imran | Jun 1994 | A |
5328467 | Edwards et al. | Jul 1994 | A |
5334196 | Scott et al. | Aug 1994 | A |
5336222 | Durgin, Jr. et al. | Aug 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5348554 | Imran | Sep 1994 | A |
5363861 | Edwards et al. | Nov 1994 | A |
5365926 | Desai | Nov 1994 | A |
5365945 | Halstrom | Nov 1994 | A |
5366490 | Edwards et al. | Nov 1994 | A |
5368557 | Nita et al. | Nov 1994 | A |
5368592 | Stern et al. | Nov 1994 | A |
5370675 | Edwards et al. | Dec 1994 | A |
5370678 | Edwards et al. | Dec 1994 | A |
5383853 | Jung et al. | Jan 1995 | A |
5383876 | Nardella | Jan 1995 | A |
5383917 | Desai | Jan 1995 | A |
5385544 | Edwards et al. | Jan 1995 | A |
5395361 | Fox et al. | Mar 1995 | A |
5397339 | Desai | Mar 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5401272 | Perkins | Mar 1995 | A |
5403311 | Abele et al. | Apr 1995 | A |
5409453 | Lundquist et al. | Apr 1995 | A |
5409483 | Campbell et al. | Apr 1995 | A |
5415657 | Taymor-Luia | May 1995 | A |
5421819 | Edwards et al. | Jun 1995 | A |
5423808 | Edwards et al. | Jun 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5423812 | Ellman et al. | Jun 1995 | A |
5428658 | Oettinger et al. | Jun 1995 | A |
5433739 | Sluijter et al. | Jul 1995 | A |
5435805 | Edwards | Jul 1995 | A |
5441499 | Fritzsch | Aug 1995 | A |
5443457 | Ginn et al. | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5448990 | De Faria-Correa | Sep 1995 | A |
5456662 | Edwards et al. | Oct 1995 | A |
5456682 | Edwards et al. | Oct 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5458597 | Edwards et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5470308 | Edwards et al. | Nov 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5472441 | Edwards et al. | Dec 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5486161 | Lax et al. | Jan 1996 | A |
5490984 | Freed | Feb 1996 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5505728 | Ellman et al. | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507743 | Edwards et al. | Apr 1996 | A |
5509419 | Edwards et al. | Apr 1996 | A |
5514130 | Baker | May 1996 | A |
5514131 | Edwards et al. | May 1996 | A |
5520684 | Imran | May 1996 | A |
5531676 | Edwards et al. | Jul 1996 | A |
5531677 | Lundquist et al. | Jul 1996 | A |
5536240 | Edwards et al. | Jul 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5540655 | Edwards et al. | Jul 1996 | A |
5549644 | Lundquist et al. | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
5554110 | Edwards et al. | Sep 1996 | A |
5556377 | Rosen et al. | Sep 1996 | A |
5558672 | Edwards et al. | Sep 1996 | A |
5558673 | Edwards et al. | Sep 1996 | A |
5562720 | Stern et al. | Oct 1996 | A |
5571116 | Bolanos et al. | Nov 1996 | A |
5578007 | Imran | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5588432 | Crowly | Dec 1996 | A |
5588960 | Edwards et al. | Dec 1996 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5609151 | Mulier et al. | Mar 1997 | A |
5624439 | Edwards et al. | Apr 1997 | A |
5658278 | Imran et al. | Aug 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5676674 | Bolanos et al. | Oct 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5688490 | Tournier et al. | Nov 1997 | A |
5702438 | Avitall | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5730698 | Fischell et al. | Mar 1998 | A |
5732698 | Swanson et al. | Mar 1998 | A |
5738096 | Ben-Haim | Apr 1998 | A |
5823197 | Edwards | Oct 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5860974 | Abele | Jan 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5957920 | Baker | Sep 1999 | A |
6006755 | Edwards | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6056744 | Edwards | May 2000 | A |
6063082 | DeVore | May 2000 | A |
6073052 | Zelickson et al. | Jun 2000 | A |
6112123 | Kelleher | Aug 2000 | A |
6197022 | Baker | Mar 2001 | B1 |
6254598 | Edwards | Jul 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6355031 | Edwards et al. | Mar 2002 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6440128 | Edwards et al. | Aug 2002 | B1 |
6464697 | Edwards et al. | Oct 2002 | B1 |
6613047 | Edwards et al. | Sep 2003 | B2 |
6699243 | West | Mar 2004 | B2 |
6748255 | Fuimaono et al. | Jun 2004 | B2 |
6749607 | Edwards et al. | Jun 2004 | B2 |
6869430 | Balbierz et al. | Mar 2005 | B2 |
6872206 | Edwards et al. | Mar 2005 | B2 |
7077841 | Gaiser et al. | Jul 2006 | B2 |
7125407 | Edwards et al. | Oct 2006 | B2 |
7179257 | West et al. | Feb 2007 | B2 |
7261722 | McGuckin et al. | Aug 2007 | B2 |
7615049 | West et al. | Nov 2009 | B2 |
7731684 | Gaiser et al. | Jun 2010 | B2 |
8647298 | West et al. | Feb 2014 | B2 |
20020077642 | Patel et al. | Jun 2002 | A1 |
20030055421 | West et al. | Mar 2003 | A1 |
20040153058 | West et al. | Aug 2004 | A1 |
20050154386 | West et al. | Jul 2005 | A1 |
20070161966 | West et al. | Jul 2007 | A1 |
20100057080 | West et al. | Mar 2010 | A1 |
20100249775 | Gaiser et al. | Sep 2010 | A1 |
20130072928 | Schaer | Mar 2013 | A1 |
Number | Date | Country |
---|---|---|
4303882 | Feb 1995 | DE |
3838840 | Feb 1997 | DE |
0139607 | May 1985 | EP |
0608609 | Aug 1994 | EP |
WO 9101773 | Feb 1991 | WO |
WO 9210142 | Jun 1992 | WO |
WO 9308755 | May 1993 | WO |
WO 9410925 | May 1994 | WO |
WO 9421165 | Sep 1994 | WO |
WO 9421178 | Sep 1994 | WO |
WO 9422366 | Oct 1994 | WO |
WO 9426178 | Nov 1994 | WO |
WO 9518575 | Jul 1995 | WO |
WO 9519142 | Jul 1995 | WO |
WO 9525472 | Sep 1995 | WO |
9600042 | Jan 1996 | WO |
WO 9616606 | Jun 1996 | WO |
9629946 | Oct 1996 | WO |
WO 9629946 | Oct 1996 | WO |
WO 9706857 | Feb 1997 | WO |
WO 9732532 | Sep 1997 | WO |
WO 9743971 | Nov 1997 | WO |
WO 9935986 | Jul 1999 | WO |
WO 9942046 | Aug 1999 | WO |
Entry |
---|
Castell, D.O. Gastroesophageal Reflux Disease: Current Strategies for Patient Management: Arch Fam. Med 5 (4): 221-7. |
Dallemagne, B. et al., “Laparoscopic Nissen Fundoplication: Preliminary,” Surgical Laparoscopy & Endoscopy. 1991 1 (3): 138-43. |
Kelly, KA et al., “Duodenal-gastric reflux and slowed gastric emptying by electrical pacing of the canine duodenal pacesetter potential,” Gastroenterology. 1997.72 (3): 429-33. |
Reynolds, J.C. “Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease,” Am J. Health-Syst Pharm. 53 (22 suppl 3): S5-12. |
Urschel, J.D. “Complications of Antireflux Surgery,” Am J. Surg. 1993. 166 (1): 68-70. |
Kaneko, et al., Physiological Laryngeal Pacemaker, May 1985, Trans Am Soc. Artif. Intern Organs, vol. XXXI, pp. 293-296. |
Mugica, et al. Direct Diaphragm Stimulation, Jan. 1987 PACE, vol. 10, pp. 252-256. |
Mugica, et al., Neurostimulation: An Overview, Chapter 21, Preliminary Test of a Muscular Diaphragm Pacing System on Human Patients. 1985. pp. 3. 263-279. |
Rice, et al., Endoscopic Paranasal Sinus Surgery, Chapter 5, Endoscopic Paranasal Sinus Surgery, The Technique of Messerklinger, Raven Press, 1988, pp. 75-104. |
Rice, et al., Endoscopic Paranasal Sinus Surgery, Chapter 6, Functional Endoscopic Paranasal Sinus Surgery, The Technique of Wigand, Raven Press, 1988, pp. 105-125. |
Karlstrom, L.H., et al., Exotopic jejuna pacemakers and enterogastric reflux after Roux gastrectomy; Effect of intestinal pacing. Surgery 1989. 106 (3): 486-495. |
Hinder; R.A., et al. “The Technique of Laparoscopic Nissen Fundoplication,” Surgical Laparoscopy & Endoscopy. 1992.2 (3): 265-272. |
Number | Date | Country | |
---|---|---|---|
20150045789 A1 | Feb 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10728684 | Dec 2003 | US |
Child | 11580543 | US | |
Parent | 09776140 | Feb 2001 | US |
Child | 10728684 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14015993 | Aug 2013 | US |
Child | 14523856 | US | |
Parent | 11580543 | Oct 2006 | US |
Child | 14015993 | US | |
Parent | 09235060 | Jan 1999 | US |
Child | 09776140 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09026316 | Feb 1998 | US |
Child | 09235060 | US |